I have recently talked to an Israeli company that started a clinical trial in moderate to severe Alzheimer's a while ago. One of the big question marks i had was - why they've chosen to enroll very advanced patients not those with an earlier stage of the disease.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.